Latest news

CEO Comment from Annual Report 2023

22 March, 2024

2023 has been marked by geopolitical tensions and macroeconomic uncertainty. Like most others, Nanologica has been affected by this and we have had to prioritize our resources. On the other hand, we operate in a market segment that is virtually insensitive to economic cycles. We expect a commercial breakthrough in the near future and have a clear growth strategy for how we can capitalize on the strong market growth that exists in drugs for the

Nanologica’s Annual Report for 2023 Has Been Published

22 March, 2024

The annual report in Swedish and a translation in English is available on www.nanologica.com in a pdf format. The official original version of the annual report is prepared in Swedish in the European Single Electronic Format (ESEF). Swedish: https://nanologica.com/category/finansiella-rapporter/ English translation: https://nanologica.com/category/financial-reports/

Subscription for Shares in Nanologica´s Rights Issue

28 February, 2024

The subscription period for shares in Nanologica´s rights issue has now started. For information on how to subscribe, please see below links: Swedish: https://nanologica.com/foretradesemission-2024/ English: https://nanologica.com/rights-issue-2024/ Subscription period: 28 Feb – 13 Mar 2024 Subscription price: SEK 6.75

Nanologica offentliggör prospekt avseende företrädesemission

23 February, 2024

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SINGAPORE, SYDAFRIKA, ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDET, PUBLICERINGEN ELLER DISTRIBUTIONEN AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG, VARA FÖREMÅL FÖR LEGALA RESTRIKTIONER ELLER SKULLE KRÄVA REGISTRERING ELLER ANDRA ÅTGÄRDER. Nanologica AB (publ) (”Nanologica” eller ”Bolaget”) offentliggör prospekt med anledning av den företrädesemission av aktier motsvarande cirka 54,2 MSEK som beslutades av styrelsen den 30 januari

Nanologica Delivers NLAB SIV™ to a Customer in Asia to a Value of over MSEK 4

12 February, 2024

Nanologica has made the first delivery of the company’s non-silica-based purification media NLAB Siv™ to a customer in Asia against an order received in November. The value amounts to over MSEK 4. NLAB Siv™ is a non-silica-based purification media that has been developed together with a customer who sells a number of pharmaceutical products. NLAB Siv™ is used for purification through preparative chromatography and the customer has expressed a desire to replace the purification media

CEO Comment Q4 2023

2 February, 2024

CEO COMMENT During the last quarter of the year, Nanologica took clear steps forward. The production problems we have wrestled with during the year have now been handled and several deliveries to customers have been made. After rigorous testing of our silica-based purification media NLAB Saga®, we made a delivery in October to one of the world’s largest insulin manufacturers in Asia against an order we received in 2022. We have been determined to ensure

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

Categories

News archive